Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension
Lund, Sweden — 31 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today positive topline results from a first clinical Phase 1 study assessing safety, tolerability, and pharmacokinetics of an investigational treprostinil subcutaneous (SC) depot (CAM2043) after single and repeated dosing in a total of 60 healthy volunteers. Results from the study showed that CAM2043 provided a dose-proportional treprostinil plasma exposure and release profile suitable for weekly, or less frequent, dosing. The tolerability of CAM2043 was generally good with no observations of unexpected or serious adverse